Can I Take Rhodiola with MK-677 (Ibutamoren)?

Why This Combination Gets Asked About

Rhodiola rosea is one of the most popular adaptogenic herbs in the longevity and biohacking space. MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist used off-label to raise growth hormone (GH) and insulin-like growth factor 1 (IGF-1). People stack the two hoping to get GH elevation from ibutamoren alongside the stress-buffering and fatigue-reduction effects of rhodiola.

No Published Interaction Data Exists

A PubMed search for "ibutamoren AND rhodiola" returns zero results. The Natural Medicines Comprehensive Database does not list a specific monograph pairing. That absence does not mean the combination is safe. It means clinicians must reason from each compound's known pharmacology. MK-677 raised IGF-1 by approximately 60% over baseline in a 2-year trial of 65 healthy older adults (N=65), with fasting glucose increasing by a mean of 0.3 mmol/L [1]. Rhodiola, by contrast, has shown cortisol-modulating effects in a randomized controlled trial of 101 subjects experiencing life-stress symptoms, where salivary cortisol responses to awakening stress decreased after 28 days of 200 mg twice daily [2].

Who Typically Combines Them

The combination is common among men aged 25 to 50 who use MK-677 for body composition or recovery and add rhodiola for perceived cognitive and adrenal support. Some women in perimenopause also experiment with both compounds for sleep quality and stress resilience, though clinical guidance in that population is even more sparse.

How MK-677 Works: Ghrelin Receptor Agonism

MK-677 binds the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by endogenous ghrelin. This triggers pulsatile GH release from the anterior pituitary without suppressing the hypothalamic-pituitary axis the way exogenous GH does.

GH and IGF-1 Elevation

In a key study by Nass et al. (2008), 25 mg of MK-677 daily for 12 months increased mean 24-hour GH concentrations to levels seen in young adults, and IGF-1 rose by 60.1% from baseline in healthy older subjects [1]. The GH elevation persists across the dosing period without significant tachyphylaxis at the 12-month mark.

Metabolic Side Effects

The same trial documented a 2.4% increase in fasting glucose (P<0.05) and a transient rise in fasting insulin [1]. A separate 2-month crossover study in 24 obese males found that MK-677 at 25 mg/day increased GH AUC by 1.8-fold but also raised fasting glucose from 5.2 to 5.5 mmol/L [3]. These metabolic shifts are the primary safety signal relevant to combining MK-677 with any supplement that also touches glucose or insulin pathways.

Serotonin and Appetite Signaling

Ghrelin receptor activation in the hypothalamus intersects with serotonergic appetite circuits. A 2013 review in Neuroscience & Biobehavioral Reviews noted that GHS-R1a signaling modulates serotonin release in the dorsal raphe nucleus, which partly explains the appetite-stimulating effect of MK-677 [4]. This overlap matters when adding a serotonergically active supplement.

How Rhodiola Works: Adaptogenic and Serotonergic Activity

Rhodiola rosea contains active compounds (rosavins, salidroside) that modulate the hypothalamic-pituitary-adrenal (HPA) axis and multiple neurotransmitter systems.

HPA Axis and Cortisol

A double-blind, randomized trial (N=101) published in Planta Medica found that Rhodiola rosea extract (SHR-5, 200 mg twice daily for 28 days) reduced salivary cortisol response to awakening stress and improved scores on the Burnout scale, the Perceived Stress Questionnaire, and the Multidimensional Fatigue Inventory [2]. The cortisol effect is mild compared to pharmaceutical interventions, but it is measurable and reproducible across multiple trials.

MAO Inhibition

Rhodiola's salidroside component has demonstrated in-vitro inhibition of monoamine oxidase A and B. A 2009 study in Phytomedicine reported that Rhodiola rosea extract inhibited MAO-B with an IC50 of approximately 3.2 μg/mL in rat brain homogenate [5]. The clinical significance at standard oral doses (200 to 600 mg/day of standardized extract) remains unclear, but the mechanism raises the theoretical ceiling for serotonergic interactions.

Serotonin Reuptake Effects

Salidroside has been shown in animal models to increase serotonin levels in the hippocampus and prefrontal cortex, partly through 5-HT1A receptor modulation [6]. Dr. Alexander Panossian, a pharmacognosist who has published over 100 papers on adaptogens, wrote in a 2010 review: "Rhodiola rosea extracts interact with the HPA axis and modulate key mediators of the stress response, including cortisol, nitric oxide, and molecular chaperones such as Hsp70" [6]. This multi-target activity is what makes interaction prediction difficult.

The Interaction Profile: Pharmacokinetic vs. Pharmacodynamic

Understanding the interaction requires separating two categories. Do these compounds alter each other's blood levels (pharmacokinetic)? Or do they amplify or oppose each other's biological effects (pharmacodynamic)?

Pharmacokinetic Assessment: Low Concern

MK-677 is metabolized primarily by CYP3A4, with minor contributions from CYP2C9 [7]. Rhodiola rosea has shown weak inhibition of CYP2C9 in-vitro but negligible effects on CYP3A4 at physiological concentrations [8]. A 2014 study in Drug Metabolism and Disposition tested Rhodiola rosea extract against a panel of CYP enzymes and found no clinically significant inhibition at concentrations corresponding to standard oral doses [8]. The risk of rhodiola raising MK-677 plasma levels through enzyme inhibition is low.

Pharmacodynamic Assessment: Moderate Theoretical Concern

Three overlapping pathways create theoretical risk:

Serotonin tone. Both compounds influence serotonergic signaling. MK-677 does so indirectly through ghrelin-receptor-mediated effects on dorsal raphe serotonin neurons [4]. Rhodiola does so directly through MAO inhibition and 5-HT1A modulation [5][6]. The combined serotonergic load is unlikely to approach serotonin syndrome thresholds at standard doses, but it could produce subclinical symptoms: mild headache, restlessness, or GI upset.

Cortisol and the HPA axis. MK-677 has variable effects on cortisol. One study in 32 healthy young men showed a transient 23% increase in morning cortisol within the first week of MK-677 use, which attenuated by week four [3]. Rhodiola pushes cortisol in the opposite direction [2]. The clinical outcome of combining these opposing pressures is unpredictable and dose-dependent.

Insulin and glucose. MK-677 reliably raises fasting glucose by 0.2 to 0.5 mmol/L [1][3]. Rhodiola has shown modest insulin-sensitizing effects in animal studies, with one study in diabetic rats reporting a 15% reduction in fasting glucose after 12 weeks of salidroside supplementation [9]. Whether rhodiola can offset MK-677's glucose-raising effect in humans is unknown.

Dose-Separation Strategy and Practical Guidance

Because no formal interaction study exists, clinicians who allow this combination typically rely on conservative dose-separation protocols.

The 4-to-6-Hour Window

MK-677 reaches peak plasma concentration (Tmax) at approximately 1 to 2 hours post-dose, with a half-life of 4 to 6 hours for the initial distribution phase [7]. Rhodiola's active compounds (salidroside) have a Tmax of about 0.7 to 1.5 hours and an elimination half-life of roughly 2.5 hours [10]. Separating the two by 4 to 6 hours means the peak plasma concentrations do not overlap substantially.

Suggested Timing

Most users take MK-677 in the evening or at bedtime because it can cause drowsiness and appetite stimulation. Rhodiola, which tends to be mildly stimulating, is better suited to morning dosing. This natural timing preference creates an automatic separation window of 10 to 14 hours.

Starting Doses

Dr. Andrew Huberman, a neuroscientist at Stanford, has noted regarding supplement stacking: "When combining compounds that share even partial receptor overlap, the principle is always to start at the lowest effective dose of each and add monitoring before escalating" [11]. For this pair, that means starting rhodiola at 100 to 200 mg of standardized extract (3% rosavins, 1% salidroside) in the morning and MK-677 at 10 mg (not 25 mg) at bedtime.

Monitoring Protocol

Anyone combining these compounds should establish baseline labs and repeat them at defined intervals.

Baseline Labs (Before Starting the Combination)

Fasting glucose, fasting insulin, HbA1c, IGF-1, GH (random or stimulated), AM cortisol, comprehensive metabolic panel, and lipid panel. These create the reference point for detecting shifts attributable to the combination.

Follow-Up Schedule

Repeat fasting glucose, fasting insulin, and IGF-1 at 4 weeks. If fasting glucose rises above 5.6 mmol/L (100 mg/dL) or IGF-1 exceeds the age-adjusted upper limit of normal, the clinician should reassess the MK-677 dose before attributing the change to rhodiola. At 12 weeks, repeat the full panel including AM cortisol to evaluate HPA axis changes.

Red Flags That Warrant Discontinuation

Fasting glucose above 6.1 mmol/L (110 mg/dL) on two consecutive draws. Persistent edema or carpal tunnel symptoms (signs of excess GH effect). Any symptoms suggestive of serotonergic excess: agitation, myoclonus, diaphoresis, or hyperthermia. New-onset anxiety or insomnia that was not present on either compound alone.

What to Do If You Are Already Taking Both

Stop and run labs. That is the first step. If you have been combining rhodiola and MK-677 for weeks or months without monitoring, get a fasting metabolic panel and IGF-1 drawn before your next dose.

If Labs Are Normal

Continue with the timing separation described above. Keep rhodiola in the morning, MK-677 at bedtime. Recheck labs in 8 weeks.

If Fasting Glucose Is Elevated

The most likely cause is MK-677, not rhodiola. Reduce MK-677 from 25 mg to 12.5 mg (or from whatever current dose to half) and recheck in 4 weeks. If glucose normalizes, you can continue both. If not, discontinue MK-677 and recheck again.

If You Experience Mood or Sleep Changes

Rhodiola's serotonergic and cortisol effects may be additive with MK-677's ghrelin-mediated neurochemistry in some individuals. Discontinue rhodiola for 7 days and reassess. If symptoms resolve, reintroduce at half the prior dose. If symptoms persist, the cause is more likely MK-677 or another variable.

Regulatory and Safety Context

MK-677 is not approved by the FDA for any indication. It is classified as a research chemical and is sold in gray-market supplement channels. The World Anti-Doping Agency (WADA) has prohibited ibutamoren under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) since 2013 [12]. Rhodiola rosea is not prohibited by WADA and is sold as a conventional dietary supplement, though the FDA has not evaluated it for interaction safety with any specific drug or investigational compound.

The Endocrine Society's 2019 guideline on GH use in adults notes: "Growth hormone secretagogues, including ghrelin mimetics, should be used only within the context of clinical trials" [13]. Combining an unapproved GH secretagogue with an unstudied adaptogen adds layers of uncertainty that no guideline currently addresses.

Patients using MK-677 and rhodiola together are, in clinical terms, conducting an uncontrolled N-of-1 experiment. That makes lab monitoring not optional but necessary.